Of those patients with KRAS mutations, they were found to have a notably higher risk of liver related metastasis (78%) and therefore may provide prognostic information for initial diagnosis or for disease progression monitoring,85 While ctDNA detection in pancreatic cancer shows clinical promise, patient's prognosis with pancreatic cancer is so poor with few therapeutic options that ctDNA's utility for clinical intervention remains limited at this time, but should be considered for prognostication and may be an avenue for targeted therapy once current management improves.86 The gene discussed is KRAS; the disease is pancreatic neoplasm.